Neeraj Agarwal

Neeraj Agarwal, MD is Director of the Genitourinary Oncology Program and Professor of Medicine at Huntsman Cancer Institute, University of Utah, and is recognized internationally as a leading clinical investigator in prostate cancer precision oncology, particularly PARP inhibitor therapy. Dr. Agarwal is best known as the global principal investigator of the TRITON2 and TRITON3 trials of rucaparib (Rubraca) in mCRPC — the pivotal studies that established rucaparib as an FDA-approved therapy for BRCA1/2-mutated mCRPC and defined the evidence base for HRR-gene-selected PARP inhibitor therapy in prostate cancer. TRITON2 (JCO 2020) demonstrated rucaparib produced a 44% confirmed ORR in BRCA1/2-mutated post-AR-therapy and post-taxane mCRPC, leading to FDA accelerated approval in 2020. TRITON3 (NEJM Evidence 2023) was the first randomized phase III trial of a PARP inhibitor versus physician's choice of AR-targeted therapy or chemotherapy in BRCA-mutated mCRPC in the post-AR-therapy setting, demonstrating a significant rPFS benefit (HR 0.61; p<0.001) for rucaparib. Beyond TRITON, Dr. Agarwal has conducted extensive research on biomarker-driven patient selection for PARP inhibitors (tumor versus germline HRR testing, reversion mutations, BRCA2 biallelic loss detection), combination PARP inhibitor plus enzalutamide strategies, and the biology of AR and DNA damage repair pathway interactions in mCRPC. He is among the most prolific clinical trial investigators in GU oncology and serves on the FDA Oncology Drug Advisory Committee for prostate cancer.